Slide 1: Quarter End Results
Quarter End Results Period Ended June 30, 2026 © Genmab 2024
Slide 2: Forward-looking Statements and Non-IFRS Financial Information
Forward-looking Statements and Non-IFRS Financial Information This presentation contains forward looking statements. The words “believe”, Further, certain forward-looking statements are based upon assumptions of future “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forw
Slide 3: First Half 2026: Strong Execution and Long-term Value Creation
First Half 2026: Strong Execution and Long-term Value Creation Focused investments & 25% total revenue growth delivering on our financial 18% adj. operating profit commitments growth* Epcoritamab: positive Phase 3 TEPKINLY®: + R2 approved in Petosemtamab: Phase 3 trials in EPCORE® DLBCL-4 results in
Slide 4: Multiple Phase 3 Readouts to Drive 2027 Launches
Multiple Phase 3 Readouts to Drive 2027 Launches Rina-S® Petosemtamab • Ph 2 2L+ PROC (RAINFOL -01) • Ph 3 1L r/m HNSCC (LiGeR-HN1) • Ph 3 2L+ PROC (RAINFOL -02) • Q4 2026 • Q4 2026 • Ph 3 2L/3L r/m HNSCC (LiGeR-HN2) • Q1 2027 EPKINLY® • Ph 3 1L DLBCL • Ph 3 2L+ DLBCL combo + len • Ph 3 2L+ DLBCL mo
Slide 5: Petosemtamab: Expanding Into Colorectal Cancer
Petosemtamab: Expanding Into Colorectal Cancer Planned Phase 3 Trials Across HNSCC and Colorectal Cancer HNSCC Colorectal Cancer (RAS BRAF Wild Type) Treatment setting Phase 3 trial Addressable Patients* Treatment setting Phase 3 trial Addressable Patients* First line LiGeR-HN1 41K First line Trial
Slide 6: Strong Growth for Proprietary Medicines in H1 2026
Strong Growth for Proprietary Medicines in H1 2026 PROPRIETARY PORTFOLIO SALES1 H1 HIGHLIGHTS +37% Proprietary portfolio delivered accelerated growth in H1, reaching an increasing number of patients around the world $396M Proven launch execution continues to grow adoption across the portfolio and ma
Slide 7: Performance Underscores Strength of Antibody Science and Launch Execution Across Markets
Performance Underscores Strength of Antibody Science and Launch Execution Across Markets NET SALES H1 HIGHLIGHTS EPKINLY® H1 2026 YoY • EPKINLY® is the only BsAb approved in both DLBCL and FL indications • Strong growth in H1 globally; Accelerated uptake in the community driven by 2L FL launch and r
Slide 8: Commercialization Excellence Will Drive Sustained Growth
Commercialization Excellence Will Drive Sustained Growth Priorities Progress Grow adoption of EPKINLY® • Strong H1 results and continued scientific and commercialization momentum across proprietary portfolio setting strong foundation to and TIVDAK® support growth trajectory Expand to new markets and
Slide 9: First Half 2026: Sustained Growth and Disciplined Investment
First Half 2026: Sustained Growth and Disciplined Investment 25% Revenue Growth Focused Investments 18% Adj. Operating Profit Growth* USD 2,051M USD 1,250M USD 656M 2% USD 554M USD 987M 15% USD 1,640M 3% 13% 83% 84% H1 2025 H1 2026 H1 2025 H1 2026 H1 2025 H1 2026 Royalties Adjusted Operating Expense
Slide 10: 2026 Improved Guidance: Revenue Growth Funds Strategic Investment
2026 Improved Guidance: Revenue Growth Funds Strategic Investment Revised Previous 19% total revenue growth*** USD Millions Guidance* Guidance** • EPKINLY® and continued momentum in royalty portfolio supports growth Revenue 4,425 4,230 and revenue quality • 5% above previous guidance 2026 Range 4,32
Slide 11: Summary: Strong Financial Foundation Positions Genmab for Growth
Summary: Strong Financial Foundation Positions Genmab for Growth Growing revenue streams and significant underlying profitability Focused and disciplined investment approach Significant growth opportunities supported by our capital allocation strategy For Investor audience only. Not for public
Slide 12: Our 2026 Capital Allocation Priorities
Our 2026 Capital Allocation Priorities: on the Path to Our Next Decade of Durable Growth Accelerating development of our late- stage pipeline and maximizing success of our commercialized medicines including launch readiness Focused integration of Merus, accelerates value capture Deleveraging:
Slide 13: Q&A Upcoming Investor Events
Q&A Upcoming Investor Events Wells Fargo 21st Annual Healthcare Confrence, September 9, 2026 Morgan Stanley 24th Annual Global Healthcare Conference, September 15, 2026 BofA Global Healthcare conference, September 22, 2026 JP Morgan European CEO Call Series, October 5, 2026 © Genmab 2026
Slide 14: Appendix
Appendix © Genmab 2026 14
Slide 15: Strategic Partnerships, Collaborations, and Licensing Agreements
Strategic As part of Genmab’s First Half 2026 Financial Results presentation, we will discuss several products developed in collaboration with strategic partners or that are the Partnerships, result of product or technology licenses with other companies. This slide is an acknowledgement of those rel
Slide 16: Condensed Income Statement: Six Months Ended June 30
Condensed Income Statement: Six Months Ended June 30 H1 2026 H1 2026 Adjusted (USD Millions) Actual Result Result* Total Revenue 2,051 2,051 Royalties 1,708 1,708 Net Product Sales/Collaboration Revenue 297 297 Milestones and Reimbursement 46 46 Gross Profit* 1,902 1,906 Operating Expenses* (1,347)
Slide 17: 2026 Improved Guidance: Revenue Growth Funds Strategic Investment
2026 Improved Guidance: Revenue Growth Funds Strategic Investment Revised Revised Previous Previous USD Millions Guidance* Mid-point* Guidance** Mid-point** 19% total revenue growth*** • EPKINLY® and continued momentum in Revenue 4,325 - 4,525 4,425 4,065 - 4,395 4,230 royalty portfolio supports gro
Slide 18: Reconciliation of Net Income to Adjusted Consolidated EBITDA
Reconciliation of Net Income to Adjusted Consolidated EBITDA Results of the Last Twelve Months (LTM) – Q2 2026 LTM Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2026 Net Profit $788 $303 $53 $31 $401 Plus/(Less): Corporate tax expense/(benefit) 118 (8) 21 24 81 Plus: Depreciation 60 14 16 16 14 Plus: Amortizat
Slide 19: Strength of Late-Stage Pipeline: Multibillion-dollar Opportunities
Strength of Late-Stage Pipeline: Multibillion-dollar Opportunities Ongoing & Announced Phase 3 Trials Opportunity Program Indication Status Addressable Patient Population* (Peak Sales) 1L DLBCL Fully Recruited 70,000 (EPCORE®DLBCL-2) 2L+ DLBCL Data January 2026 (EPCORE®DLBCL-1) 21,000 2L+ DLBCL EPKI